Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia

Experimental Hematology

Volumn 44, Issue 11, 2016, Pages 1039-1043.e10

  Laverdière, Isabelle ^a   Boileau, Meaghan ^a   Herold, Tobias ^b   Rak, Janusz ^a   Berdel, Wolfgang E ^c   Wörmann, Bernhard ^d   Hiddemann, Wolfgang ^b   Spiekermann, Karsten ^b   Bohlander, Stefan K ^e   Eppert, Kolja ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; TRANSCRIPTOME;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CFD GENE; CFH GENE; COHORT ANALYSIS; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SERPING1 GENE; VERY ELDERLY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; KAPLAN MEIER METHOD; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; NUCLEIC ACID DATABASE; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CLUSTER ANALYSIS; COHORT STUDIES; DATABASES, NUCLEIC ACID; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REGULATORY NETWORKS; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84992593487     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.07.012     Document Type: Article

References (18)

1. 1 Dohner, H., Estey, E.H., Amadori, S., et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (2010), 453–474.
2. 2 Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: A key system for immune surveillance and homeostasis. Nat Immunol 11 (2010), 785–797.
3. 3 Mamidi, S., Hone, S., Teufel, C., Sellner, L., Zenz, T., Kirschfink, M., Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology, 4, 2015, e979688.
4. 4 Markiewski, M.M., Lambris, J.D., Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30 (2009), 286–292.
5. 5 Campa, M.J., Gottlin, E.B., Bushey, R.T., Patz, E.F. Jr., Complement factor H antibodies from lung cancer patients induce complement-dependent lysis of tumor cells, suggesting a novel immunotherapeutic strategy. Cancer Immunol Res 3 (2015), 1325–1332.
6. 6 Kesselring, R., Thiel, A., Pries, R., et al. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. Eur J Cancer 50 (2014), 2152–2161.
7. 7 Herold, T., Metzeler, K.H., Vosberg, S., et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood 124 (2014), 1304–1311.
8. 8 Verhaak, R.G., Wouters, B.J., Erpelinck, C.A., et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94 (2009), 131–134.
9. 9 Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res 42:Database Issue (2014), D199–D205.
10. 10 Li, Z., Herold, T., He, C., et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: An international collaborative study. J Clin Oncol 31 (2013), 1172–1181.
11. 11 Junnikkala, S., Hakulinen, J., Jarva, H., et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 87 (2002), 1119–1127.
12. 12 Kitano, E., Kitamura, H., Synthesis of factor D by gastric cancer-derived cell lines. Int Immunopharmacol 2 (2002), 843–848.
13. 13 Sakhinia, E., Faranghpour, M., Liu Yin, J.A., Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol 130 (2005), 233–248.
14. 14 Cho, M.S., Vasquez, H.G., Rupaimoole, R., et al. Autocrine effects of tumor-derived complement. Cell Rep 6 (2014), 1085–1095.
15. 15 Eppert, K., Takenaka, K., Lechman, E.R., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17 (2011), 1086–1093.
16. 16 Toren, A., Bielorai, B., Jacob-Hirsch, J., et al. CD133-positive hematopoietic stem cell “stemness” genes contain many genes mutated or abnormally expressed in leukemia. Stem Cell 23 (2005), 1142–1153.
17. 17 Wysoczynski, M., Reca, R., Lee, H., Wu, W., Ratajczak, J., Ratajczak, M.Z., Defective engraftment of C3aR–/– hematopoietic stem progenitor cells shows a novel role of the C3a C3aR axis in bone marrow homing. Leukemia 23 (2009), 1455–1461.
18. 18 Reca, R., Mastellos, D., Majka, M., et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 101 (2003), 3784–3793.